top of page
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Not compatible with Internet Explorer
Search
NLS Pharmaceutics and Kadimastem Highlight Continued BIRD Foundation Support for ITOL-102 Diabetes Program Following Merger
Zurich, Switzerland – October 28, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS” or the “Company”), a biopharmaceutical company focused on developing innovative therapies for central nervous system and neurodegenerative disorders, and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes today announced that the ITOL-102 cell therapy program for Type 1 Diabetes, originally sup
2 hours ago4 min read
Kadimastem Announces Strategic Collaboration with TargetGene to Advance Next-Generation Gene-Edited Cell Therapies
The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger Zurich, Switzerland and Ness Ziona, Israel – October 27, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP) (“NLS”), a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”), a clinical-stage biotechnology company developing breakthrough cell therapy solutions for seve
2 days ago5 min read
NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025
Zurich, Switzerland – October 23, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS” or the “Company”), a Swiss clinical-stage biopharmaceutical company focused on central nervous system (“CNS”) disorders, and Kadimastem Ltd. (TASE: KDST) (“Kadimastem”) , an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes, today announced an update regarding the proposed merger (the “Merger”). On October 21, 2025, NLS r
6 days ago6 min read
NLS Pharmaceutics Shareholders Approve Merger with Kadimastem and Related Proposals at Extraordinary General Meeting
Vote clears final corporate milestone, paving the way for the closing of the merger and the combined company of NewCelX Ltd., a...
Sep 305 min read
Kadimastem and NLS Pharmaceutics Announce Effectiveness of SEC Registration Statement in Connection with Proposed Merger
Zurich, Switzerland and Ness Ziona, Israel – September 10, 2025 – NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW) (“NLS”), a Swiss...
Sep 106 min read
NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients
Patent grant broadens IP protection in Asia and complements prior patents in Europe, the United States and India. Hong Kong represents a...
Sep 46 min read
The BIRD Foundation Approves Approves Additional Milestone Payment to Kadimastem and iTolerance for Continued Co-Development of Type 1 Diabetes Cell Therapy
Approval Follows Successful Pre-IND Meeting with the U.S. FDA on iTOL-102, a Potential Cure for Type 1 diabetes that would circumvent the...
Jul 175 min read
Kadimastem Shares that NLS Pharmaceutics CEO Issues Letter to Shareholders
Advancing Toward Merger Completion and Clinical Milestones with Strengthened Financial Backing, as Joint Pipeline Gains Momentum in ALS,...
Jun 168 min read
Kadimastem and NLS Pharmaceutics Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement
The equity financing is at a 10% premium to the market share price [1] ZÜRICH, Switzerland, March 31, 2025 - NLS Pharmaceutics Ltd. ...
Mar 317 min read
Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment
Companies Advance Collaborative Clinical Development of iTOL-102: A Potential Cure for Diabetes Without the Need for Chronic Life-long...
Feb 258 min read
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
Revolutionizing Diabetes Treatment : Introduction of cutting-edge, multi-targeted innovation to transform diabetes care. Diabetes more...
Feb 108 min read
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
Kadimastem Approaches Final Steps for Securing Merger Completion ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL— January 16th 2025 — NLS...
Jan 167 min read
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting
Was sold at Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025 ZURICH, SWITZERLAND and NESS ZIONA,...
Jan 87 min read
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical...
Dec 31, 20247 min read
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
This submission comes after successful INTERACT meeting with the FDA earlier this year. NLS Pharmaceutics and Kadimastem working to close...
Dec 19, 20248 min read
The BIRD Foundation has Approved an Additional Payment to Kadimastem and Miami Based iTolerance Inc. from the Total Grant for the Continued Co-Development of the Innovative Treatment for Diabetes
The Additional Payment is for the Progress Presented by the Companies in the Development of the Treatment Ness Ziona, Israel, November...
Nov 27, 20246 min read
Vote of Confidence by Major Kadimastem Shareholder in the Merger Transaction with Swiss Biopharma Company NLS Pharmaceutics
Prof. Michel Revel, a company founder, who serves as the company's chief scientist, director and substantial shareholder who invented a...
Nov 17, 20246 min read
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL /November 5th, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP) ("NLS"), a biopharmaceutical...
Nov 5, 20245 min read
Kadimastem completes another stage towards the merger with NLS Pharmaceutics, which has Regained Full Compliance with Nasdaq Listing Requirements
Ness Ziona, Israel October 29, 2024 -Kadimastem Ltd (“KDST.TA”, “Kadimastem”), a clinical-stage cell therapy company developing and...
Oct 29, 20244 min read
Kadimastem Ltd. and NLS Pharmaceutics Announce Binding Term Sheet to Merge
The proposed transaction will create a Nasdaq-traded, biotechnology company with product candidates in advanced stages of clinical...
Jul 29, 20246 min read
bottom of page